Generic Iclusig

At this time, Iclusig (ponatinib) tablets are available in brand-name form only. However, after the first patent for the drug expires in December 2026, companies may be allowed to make a generic version of it. Although ponatinib is often referred to as the "generic name" for Iclusig, it is simply the active ingredient in this medicine and is not a generic version of it.

Can I Buy Generic Iclusig?

Iclusig® (ponatinib) is a prescription medication used in the treatment of leukemia. It comes as a tablet that is usually taken once daily.
Iclusig is made by ARIAD Pharmaceuticals, Inc. It is currently protected from generic competition by patents that have not yet expired.

When Will a Generic Version Be Available?

The first patent for Iclusig is set to expire in December 2026. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or other patents for new Iclusig uses. Once the patent expires, there may be several companies that manufacture a generic Iclusig drug.

Is Ponatinib a Generic Iclusig?

No -- ponatinib is the active ingredient in Iclusig, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
The Zen of Cancer Caregiving - Recharge Your Batteries!

Iclusig Chemotherapy Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.